On February 2, 2022, Drs. Ameet Sarpatwari, Aaron S. Kesselheim, Jerry Avorn, and Benjamin N. Rome of Harvard Medical School and Dr. Michael S. Sinha of Northeastern University and Loyola University sent a letter to HHS Secretary Xavier Becerra in… Continue Reading →
Published in an article by Sydney Lupkin of NPR, the Pfizer-US government contract for the COVID-19 therapeutic Paxlovid contains terms of interest in broader drug pricing discussions. The Pfizer contract includes a “Most Favored Nation Clause” (H.7), which provides that… Continue Reading →
(For more information, please see the Xtandi: 2021-2022 request page) A January 25, 2022 Knowledge Ecology International “Memorandum in support of the petition to HHS to exercise the march-in or paid up royalty right in patents on the prostate drug… Continue Reading →
New: March 21, 2023. The NIH sent a response to the Xtandi petition, rejecting the request to use the governments’ rights to lower the price of the prostate cancer treatment. New: March 23, 2023. The petitioners filed an appeal to… Continue Reading →
Update: Video recording of the press briefing available here: https://www.youtube.com/watch?v=KwqUl7NLMXo) December 15th 10AM – Briefing on Xtandi March-in Request Supporters of the march-in petition to lower the cost of the prostate cancer drug Xtandi will host a virtual press conference… Continue Reading →
On December 13, 2021, Eric Sawyer filed this petition with the Department of Health and Human Services, asking to join an outstanding march-in petition on the patents for the prostate cancer drug enzalutamide, sold under the brand name Xtandi by… Continue Reading →
(Update: On December 15, 2021 KEI hosted a press briefing regarding the Xtandi march-in request. Video and details available here: https://www.youtube.com/watch?v=KwqUl7NLMXo) On November 18, 2021, Robert Sachs and Clare Love submitted a petition to the Secretary of Health and Human… Continue Reading →
Robert Sachs filed this petition with DoD, asking to join an outstanding march-in petition on the patents for the prostate cancer drug enzalutamide, sold under the brand name Xtandi by Astellas. The petition asks that that march-in be granted on… Continue Reading →
The following records were provided by KEI from UCLA on September 28, 2018, following a freedom of Records Request. This page describes the contents of on very large PDF file, the “Combined IN Writ Petition DHC,” which is 1,309 pages long,… Continue Reading →
For a general timeline of the Bayh-Dole Act, see this page. 1999. September 3. Ralph Nader, James Love, and Robert Weissman requests the NIH Director Harold Varmus, M.D., to use royalty-free rights and give the WHO access to several U.S. government… Continue Reading →